These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6752959)

  • 1. Inhibition of platelet aggregation and reversal of vasopressin-induced ECG changes by a carboprostacyclin analogue, ONO 41483, in primates.
    Adaikan PG; Kottegoda SR; Lau LC; Tai MY; Karim SM
    Prostaglandins Leukot Med; 1982 Sep; 9(3):307-20. PubMed ID: 6752959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of platelet aggregation with intravenous and oral administration of a carboprostacyclin analogue, 15-cyclopentyl-omega-pentanor-5(E)-carbacyclin (ONO 41483) in man.
    Adaikan PG; Lau LC; Tai MY; Karim SM
    Prostaglandins Leukot Med; 1983 Jan; 10(1):53-64. PubMed ID: 6338531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of platelet aggregation and antagonism of vasopressin-induced ECG changes in primates by a carboprostacyclin analogue, ZK 36374.
    Adaikan PG; Karim SM; Lau LC; Tai MY; Kottegoda SR
    Thromb Res; 1984 Feb; 33(3):333-40. PubMed ID: 6200948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet and other effects of carboprostacyclin--a stable prostacyclin analogue.
    Adaikan PG; Karim SM; Lau LC
    Prostaglandins Med; 1980 Oct; 5(4):307-20. PubMed ID: 7003626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation.
    Whittle BJ; Moncada S; Whiting F; Vane JR
    Prostaglandins; 1980 Apr; 19(4):605-27. PubMed ID: 6992234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of platelet aggregation with intravenous and oral administration of carboprostacyclin in man.
    Karim SM; Adaikan PG; Lau LC; Tai MY
    Prostaglandins Med; 1981 May; 6(5):521-7. PubMed ID: 7022510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of vasopressin-induced coronary vasoconstriction by a PGE1 analogue (ONO 1206) in primates.
    Kottegoda SR; Adaikan PG; Karim SM
    Prostaglandins Leukot Med; 1982 Apr; 8(4):343-8. PubMed ID: 6955802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison in anesthetized dogs of the anti-aggregatory and hemodynamic effects of prostacyclin and a chemically stable prostacyclin analog, 6a-carba-PGI2 (carbacyclin).
    Aiken JW; Shebuski RJ
    Prostaglandins; 1980 Apr; 19(4):629-43. PubMed ID: 6992235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cardiovascular and platelet actions of 9 beta-methyl carbacyclin (ciprostene), a chemically stable analogue of prostacyclin, in the dog and monkey.
    Allan G; Follenfant MJ; Lidbury P; Oliver PL; Whittle BJ
    Br J Pharmacol; 1985 Jun; 85(2):547-55. PubMed ID: 3896365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.
    O'Grady J; Hedges A; Whittle BJ; Al-Sinawi LA; Mekki QA; Burke C; Moody SG; Moti MJ; Hassan S
    Br J Clin Pharmacol; 1984 Dec; 18(6):921-33. PubMed ID: 6085004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new stable prostacyclin analogue OP41483 (15-cyclopentyl-omega-pentanor-5(E)-carbacyclin).
    Yui Y; Takatsu Y; Hattori R; Kawai C; Osaki Y; Yohida T
    Jpn Circ J; 1985 Jun; 49(6):571-5. PubMed ID: 3897597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. dl-9a-Deoxy-9a-methylene-PGI2 (a stable prostacyclin derivative): preliminary pharmacological data.
    Ceserani R; Grossoni M; Longiave D; Mizzotti B; Pozzi O; Dembinska-Kiec A; Bianco S
    Prostaglandins Med; 1980 Aug; 5(2):131-9. PubMed ID: 6251496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Iloprost (ZK 36 374), a novel prostacyclin analogue, on ADP-induced platelet aggregation.
    Wadenvik H; Kutti J
    Acta Haematol; 1985; 73(4):224-7. PubMed ID: 2414956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue.
    Whittle BJ; Moncada S; Mullane K; Vane JR
    Prostaglandins; 1983 Feb; 25(2):205-23. PubMed ID: 6344147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Some pharmacological effects of 17(S) methyl-omega-homo-trans-delta2-PGE1 (ONO 1206).
    Adaikan PG; Karim SM
    Prostaglandins Med; 1981 Apr; 6(4):449-58. PubMed ID: 7280119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular and platelet effects in man of BW 245C, a stable mimic of epoprostenol (PGI2).
    Orchard MA; Ritter JM; Shepherd GL; Lewis PJ
    Br J Clin Pharmacol; 1983 May; 15(5):509-11. PubMed ID: 6344895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of prostacyclin on platelet-activating factor induced rabbit and platelet aggregation.
    Bussolino F; Camussi G
    Prostaglandins; 1980 Nov; 20(5):781-91. PubMed ID: 6258196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relative activity of prostacyclin (PGI2) and a stable analogue 6beta-PGI1 on the gastrointestinal and cardiovascular systems.
    Whittle BJ; Boughton-Smith NK; Moncada S; Vane JR
    J Pharm Pharmacol; 1978 Sep; 30(9):597-9. PubMed ID: 29109
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of platelet aggregation by a new agent, 5-(Z,E)-13,14-didehydro-20-methyl-carbo PGI2 (FCE 22509).
    Bergamaschi M; Pierucci L; Ferti C; Corsi G; Branzoli U; Mandelli V
    Prostaglandins Leukot Med; 1984 Oct; 16(1):19-27. PubMed ID: 6393142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the activities of prostacyclin and its stable analogs on the platelet aggregation and cardiovascular systems.
    Kawasaki A; Ishii K; Wakitani K; Tsuboshima M
    Adv Prostaglandin Thromboxane Res; 1980; 6():331-6. PubMed ID: 6992531
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.